欢迎来到抗癌健康网!  
放入收藏夹 | 返回首页

PSA筛查不能预测前列腺癌特异性死亡事件

2019-04-12

抗癌健康网

手机看网页

导读:筛查组和对照组患者前列腺癌特异性死亡事件欧洲前列腺癌随机筛查研究(ERSPC)结果提示应用前列腺特异性抗原

 欧洲前列腺癌随机筛查研究(ERSPC)结果提示应用前列腺特异性抗原对前列腺癌进行筛查能降低前列腺癌的死亡率。来自芬兰Tampere大学的Tuomas P等评估了芬兰前列腺癌筛查研究(ERSPC的最大的组成部分)中死亡率的相关的结果。本研究的主要终点事件为前列腺癌特异性死亡率。他们的研究结果发表在JNCI 3月的在线期刊上。

研究者从登记在册的人口中共纳入了80144名男性,他们被随机分为2组,一组为筛查组(SA),另一组为对照组(CA)。在筛查组的受试者每隔4年进行一次PSA筛查,共进行3次测定,如果其PSA浓度大于等于4.0ng/mL或PSA浓度介于3.0至3.9ng/mL但游离PSA/总PSA小于等于16%的话,那么研究者建议其进行前列腺活检。在研究中,研究者对所有入组的受试者都进行了为期长达12年的随访。研究者采用Cox风险比例模型估计了前列腺癌发病率和死亡率的风险比。所有的统计检验都在双侧进行。

前列腺癌的发病率在筛查组中为8.8/1000人-年,在对照组则为6.6/1000人-年,风险比为1.34,95%可信区间为1.27至1.40。与对照组相比,筛查组的晚期前列腺癌发病率更低,两组分别为1.6和1.2,风险比为0.73,两组差异具有显著统计学意义。研究者需要就1199人进行筛查且在其中发现25例前列腺癌患者才能避免1例前列腺癌特异性死亡事件。研究者没有观察到所有原因造成的死亡率在两组中存在差异。

本研究结果提示,在第12年时,一项相对保守的筛查方案仅能带来前列腺癌特异性死亡率的微弱及不具统计学显著意义的降低,但是其所付出的代价则是对患者的过度诊断。(生物谷Bioon.com)

doi:10.1093/jnci/djt038
PMC:
PMID:

Prostate Cancer Mortality in the Finnish Randomized Screening Trial
 

Kilpel?inen TP Tammela TL Malila N Hakama M Santti H M??tt?nen L Stenman UH Kujala P Auvinen A
 

Prostate cancer (PC) screening with prostate-specific antigen (PSA) has been shown to decrease PC mortality by the European Randomized Study of Screening for Prostate Cancer (ERSPC). We evaluated mortality results in the Finnish Prostate Cancer Screening Trial, the largest component of ERSPC. The primary endpoint was PC-specific mortality.MethodsA total of 80 144 men were identified from the population registry and randomized to either a screening arm (SA) or a control arm (CA). Men in the SA were invited to serum PSA determination up to three times with a 4-year interval between each scan and referred to biopsy if the PSA concentration was greater than or equal to 4.0ng/mL or 3.0 to 3.99ng/mL with a free/total PSA ratio less than or equal to 16%. Men in the CA received usual care. The analysis covers follow-up to 12 years from randomization for all men. Hazard ratios (HRs) were estimated for incidence and mortality using Cox proportional hazard model. All statistical tests were two-sided.ResultsPC incidence was 8.8 per 1000 person-years in the SA and 6.6 in the CA (HR = 1.34, 95% confidence interval [CI] = 1.27 to 1.40). The incidence of advanced PC was lower in the SA vs CA arm (1.2 vs 1.6, respectively; HR = 0.73, 95% CI = 0.64 to 0.82; P < .001). For PC mortality, no statistically significant difference was observed between the SA and CA (HR = 0.85, 95% CI = 0.69 to 1.04) (with intention-to-screen analysis). To avoid one PC death, we needed to invite 1199 men to screening and to detect 25 PCs. We observed no difference in all-cause mortality between trial arms.ConclusionsAt 12 years, a relatively conservative screening protocol produced a small, non-statistically significant PC-specific mortality reduction in the Finnish trial, at the cost of moderate overdiagnosis.

文章转载于网络,仅供阅读浏览,未做任何商业用途,如有侵权请联系删除!

[关键词: 前列腺癌 ]

在这里,掌握健康资讯

扫描左侧二维码即可添加抗癌健康网官方微信;
健康之路 与你同行
前列腺癌更多>>
前列腺癌在欧美是男性癌死亡的主要原因之一,发病率随年龄增长,80岁以上检查前列腺半数有癌病灶。[详情]
热文欣赏更多>>

健康阅读

推荐欣赏

  • 热门推荐
  • 最新期刊
  • 疾病关注
长期憋尿,膀胱癌,长期憋尿引发膀胱癌
[详情]
白血病与骨髓移植术
[详情]
筷子致癌?靠什么吃饭?
[详情]
卵巢囊肿并不可怕
[详情]
调理内分泌多吃黄色食物
[详情]
吃腐乳致癌可信吗?
[详情]
资讯排行榜更多>>
肺癌康复指南吃什么?
信息聚焦更多>>
化疗药物中成药止痛药
多西他赛鸦胆子油口服液阿司匹林
依托泊苷注射液十三味菥蓂丸扑热息痛
卡铂通迪胶囊盐酸哌替啶片
5-氟尿嘧啶(5-FU)乌金活血胶囊吗啡
顺铂(PDD)血尿胶囊芬太尼
视频推荐更多>>
肿瘤热文欣赏更多>>

特别声明:本站信息仅供参考 不能作为诊断及医疗的依据平台联系我们

抗癌健康网 版权所有 未经授权请勿转载  CopyRight©2008-2018 www.ca39.com, All Rights Reserved. 浙ICP备11014848号